tbResList Print — MSM Methylsulfonylmethane

Filters: qv=124, qv2=%, rfv=%

Product

MSM Methylsulfonylmethane
Description: <b>MSM (Methylsulfonylmethane)</b> is a naturally occurring organosulfur compound often used as a dietary supplement for its anti-inflammatory and antioxidant effects. While most well-known for joint health.<br>
-MSM is actually a metabolite of DMSO (dimethyl sulfoxide)
<pre>
-Generally Recognized as Safe Possible Interactions: aspirin, warfarin, NSAIDS<br>
-Supplement dosage: 500mg 2-3times/day<br>

-Anti-inflammatory: ↓NF-κB, ↓COX-2 and iNOS
-↓STAT3
-↓Cyclin D1 and CDK4, halting cell cycle progression.
-↓MMP-2, MMP-9, VEGF limiting invasion.

</pre>




<p><b>Methylsulfonylmethane (MSM)</b> — a small, naturally occurring organosulfur compound, also called dimethyl sulfone, that is formed in sulfur metabolism and is also a major oxidation product/metabolite of dimethyl sulfoxide (DMSO). It is classified primarily as a dietary supplement/nutraceutical rather than an approved anticancer drug. Standard abbreviations are MSM and DMSO₂. MSM occurs at low levels in foods and biological fluids and is widely used orally for musculoskeletal and inflammatory conditions. Its most reproducible biology is anti-inflammatory and redox-modulating, whereas anticancer effects remain predominantly preclinical and frequently require very high concentrations.</p>

<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Suppression of STAT3/STAT5b signaling and associated oncogenic transcription, including IGF-1R, HER2 and VEGF pathways.</li>
<li>Suppression of hypoxia-driven HIF-1α signaling, with downstream reduction of glycolytic and metastatic programs including GLUT1, LDHA, PKM2 and VEGF.</li>
<li>Induction of cancer-cell growth arrest and apoptosis, including caspase activation and PARP cleavage in susceptible models.</li>
<li>Suppression of NF-κB-driven inflammatory signaling and inflammatory mediators including COX-2, iNOS, TNF-α, IL-1β and IL-6.</li>
<li>Suppression of NLRP3 inflammasome activation and mitochondrial ROS-dependent inflammatory signaling.</li>
<li>Reduction of migration, invasion and angiogenic/metastatic signaling, particularly through STAT/HIF-1α/VEGF-related pathways.</li>
<li>Antioxidant/redox-buffering activity in normal or inflammatory tissues, generally reducing excessive ROS rather than acting as a cancer-selective pro-oxidant.</li>
</ol>

<p><b>Bioavailability / PK relevance:</b> MSM is orally absorbed and distributes widely into tissues, including the central nervous system. Human serum concentrations increase during repeated oral supplementation, and available data suggest a systemic half-life greater than approximately 12 hours. Common studied oral doses are approximately 1.5–6 g/day. Oral absorption is therefore not the major translational limitation; the main limitation for cancer applications is the very large exposure gap between supplement-level systemic concentrations and the concentrations used in many anticancer experiments.</p>

<p><b>In-vitro vs systemic exposure relevance:</b> This is a major limitation. Many direct anticancer studies use approximately 100–500 mM MSM; breast-cancer studies commonly used approximately 300 mM and liver-cancer experiments up to 500 mM. Gastrointestinal cancer IC50 values of approximately 22–28 mg/mL correspond to roughly 230–300 mM. These concentrations are orders of magnitude above the low-micromolar endogenous/systemic range and are unlikely to be reproduced by conventional oral supplementation. Consequently, direct cytotoxic anticancer mechanisms should not be assumed to occur at typical human oral doses.</p>

<p><b>Clinical evidence status:</b> Human evidence exists mainly for osteoarthritis, pain, exercise/inflammation and cosmetic/skin outcomes, including small randomized controlled trials using approximately 3–6 g/day. Cancer evidence is preclinical, consisting of cell culture and animal/xenograft studies; convincing human anticancer efficacy has not been demonstrated. MSM should therefore be categorized as preclinical for cancer rather than as an established oncology adjunct.</p>


<br>
<h3>Methylsulfonylmethane Cancer Mechanisms</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>

<tr>
<td>1</td>
<td>STAT3 and STAT5b oncogenic signaling</td>
<td>STAT3 ↓; STAT5b ↓; transcriptional activity ↓</td>
<td>↔ (limited evidence)</td>
<td>R, G</td>
<td>Survival and proliferative signaling ↓</td>
<td>One of the strongest cancer-specific MSM mechanisms. Breast and bladder models show suppression of STAT3/STAT5b and downstream oncogenic transcription, but most experiments use concentrations far above achievable systemic exposure.</td>
</tr>

<tr>
<td>2</td>
<td>IGF-1R and HER2 growth signaling</td>
<td>IGF-1R ↓; HER2 ↓; Brk/PTK6 ↓ (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Growth signaling ↓</td>
<td>STAT5b-dependent repression of HER2 has been demonstrated in breast-cancer cells; IGF-1R suppression accompanies STAT pathway inhibition in several tumor models.</td>
</tr>

<tr>
<td>3</td>
<td>Hypoxia HIF-1α and glycolytic program</td>
<td>HIF-1α ↓; GLUT1 ↓; PKM2 ↓; LDHA ↓</td>
<td>↔</td>
<td>R, G</td>
<td>Hypoxic adaptation and glycolysis ↓</td>
<td>Under hypoxia, MSM has been reported to suppress HIF-1α and several downstream metabolic adaptations associated with aggressive metastatic phenotypes.</td>
</tr>

<tr>
<td>4</td>
<td>VEGF angiogenic signaling</td>
<td>VEGF ↓; VEGFR2 ↓ (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Angiogenic signaling ↓</td>
<td>Closely linked to STAT3 and HIF-1α suppression. Reduced VEGF expression has been demonstrated in breast and bladder tumor models.</td>
</tr>

<tr>
<td>5</td>
<td>Apoptotic caspase pathway</td>
<td>Apoptosis ↑; caspase-8 ↑; caspase-3 ↑; PARP cleavage ↑; Bcl-2 ↓</td>
<td>↔ (model-dependent)</td>
<td>G</td>
<td>Programmed cell death ↑</td>
<td>Documented in breast, hepatic and gastrointestinal cancer models. Direct apoptosis generally occurs at high millimolar concentrations.</td>
</tr>

<tr>
<td>6</td>
<td>Cell-cycle arrest</td>
<td>G2/M arrest ↑; proliferation ↓</td>
<td>↔</td>
<td>G</td>
<td>Cytostasis</td>
<td>Gastrointestinal cancer models show accumulation in G2/M. Cell-cycle effects are secondary to broader signaling disruption and require high concentrations in many studies.</td>
</tr>

<tr>
<td>7</td>
<td>Migration and metastatic phenotype</td>
<td>Migration ↓; invasion ↓; metastatic signaling ↓</td>
<td>↔</td>
<td>G</td>
<td>Metastatic potential ↓</td>
<td>Associated with inhibition of STAT3/STAT5b, VEGF, hypoxia signaling and metabolic reprogramming.</td>
</tr>

<tr>
<td>8</td>
<td>NF-κB inflammatory transcription</td>
<td>NF-κB ↓ (context-dependent)</td>
<td>NF-κB ↓; COX-2 ↓; iNOS ↓; TNF-α ↓; IL-1β ↓; IL-6 ↓</td>
<td>R, G</td>
<td>Inflammatory signaling ↓</td>
<td>This is better established in macrophages, monocytes and inflammatory tissue models than as a direct cancer-cell mechanism. It may nevertheless alter inflammation-associated tumor biology.</td>
</tr>

<tr>
<td>9</td>
<td>NLRP3 inflammasome</td>
<td>NLRP3 ↓ (context-dependent)</td>
<td>NLRP3 ↓; IL-1β ↓; mitochondrial ROS ↓</td>
<td>R, G</td>
<td>Inflammasome activation ↓</td>
<td>MSM selectively suppresses NLRP3 activation in macrophage models. This is principally an anti-inflammatory mechanism rather than demonstrated direct tumor cytotoxicity.</td>
</tr>

<tr>
<td>10</td>
<td>ROS and oxidative stress buffering</td>
<td>ROS ↓ (generally; context-dependent)</td>
<td>ROS ↓; oxidative injury ↓</td>
<td>P, R</td>
<td>Antioxidant activity</td>
<td>MSM should generally be classified as ROS-lowering rather than ROS-generating. This distinguishes it from many anticancer agents whose cytotoxicity depends on oxidative stress.</td>
</tr>

<tr>
<td>11</td>
<td>Radiosensitization or Chemosensitization</td>
<td>Synergy ↑ with selected targeted agents (preclinical); ROS-dependent therapy interaction uncertain</td>
<td>Oxidative and inflammatory injury ↓ (possible)</td>
<td>G</td>
<td>Context-dependent adjunct effect</td>
<td>Synergy has been demonstrated experimentally with the JAK2 inhibitor AG490. There is insufficient evidence to classify MSM broadly as a chemo- or radiosensitizer, and its antioxidant properties create a theoretical concern with strongly ROS-dependent treatments.</td>
</tr>

<tr>
<td>12</td>
<td>Clinical Translation Constraint</td>
<td>Required direct anticancer concentrations often approximately 100–500 mM</td>
<td>Oral doses approximately 1.5–6 g/day generally tolerated short term</td>
<td>G</td>
<td>Exposure mismatch</td>
<td>The large concentration gap between anticancer cell-culture experiments and achievable oral systemic exposure is the principal translational constraint. Human anticancer efficacy has not been established.</td>
</tr>
</table>
<p>P: 0–30 min&nbsp;&nbsp;&nbsp; R: 30 min–3 hr&nbsp;&nbsp;&nbsp; G: &gt;3 hr</p>









<br><br>
<hr>
<br><br>


For Alzheimer's (AD):<br>
Methylsulfonylmethane (MSM) in neurobiology is primarily framed as an anti-inflammatory and redox-buffering molecule, not a direct amyloid-clearing or tau-targeting drug. Evidence is largely preclinical (cell + animal models). Position it as a neuroinflammation and oxidative stress modulator.<br>
<pre>
-Anti-inflammatory: ↓TNF-α, IL-1β, IL-6
-↓ROS, ↑GSH, ↓NO
-may reduce Aβ plaque burden and tau hyperphosphorylation indirectly
-improves memory in rodents
</pre>
<p><b>Methylsulfonylmethane and Alzheimer’s disease:</b> MSM has preliminary neuroprotective evidence but no established human Alzheimer’s disease efficacy. In a rat model of BPA plus γ-radiation-induced AD-like neurotoxicity, MSM reduced oxidative stress and neuroinflammation and ameliorated elevations of Aβ42, phosphorylated tau and acetylcholinesterase while modulating TREM2/DAP12/SYK signaling. Because this is an experimentally induced neurotoxicity model rather than spontaneous human AD, these findings should be classified as preclinical and model-dependent. MSM reaches the human brain, supporting biological plausibility for CNS activity, but therapeutic CNS exposure-response relationships remain poorly defined.</p>

<p><b>Clinical evidence status:</b> Preclinical only for Alzheimer-related outcomes. There are no convincing randomized human trials establishing MSM as an AD treatment.</p>



<br>
<h3>Methylsulfonylmethane Alzheimer-Relevant Mechanisms</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Modulation</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>

<tr>
<td>1</td>
<td>Neuroinflammation</td>
<td>TNF-α ↓; IL-1β ↓; inflammatory signaling ↓</td>
<td>R, G</td>
<td>Neuroinflammatory burden ↓</td>
<td>Supported in an AD-like toxin/radiation rat model and consistent with the broader anti-inflammatory pharmacology of MSM.</td>
</tr>

<tr>
<td>2</td>
<td>Oxidative stress</td>
<td>Oxidative stress ↓</td>
<td>P, R</td>
<td>Redox injury ↓</td>
<td>A central protective mechanism across MSM neurotoxicity and inflammatory models.</td>
</tr>

<tr>
<td>3</td>
<td>TREM2 DAP12 SYK signaling</td>
<td>Pathologic activation ↓ toward control</td>
<td>R, G</td>
<td>Microglial signaling normalization</td>
<td>Directly examined in the BPA plus γ-radiation neurodegeneration model.</td>
</tr>

<tr>
<td>4</td>
<td>Amyloid beta pathology</td>
<td>Aβ42 ↓; Aβ deposition ↓</td>
<td>G</td>
<td>Amyloid-associated pathology ↓</td>
<td>Demonstrated in one AD-like rat model; should not be interpreted as proof of direct amyloid-targeting activity in human AD.</td>
</tr>

<tr>
<td>5</td>
<td>Tau phosphorylation</td>
<td>p-tau ↓</td>
<td>G</td>
<td>Tau-associated pathology ↓</td>
<td>Observed in the same toxin/radiation rat model. The responsible kinase/phosphatase mechanism was not established as a primary MSM target.</td>
</tr>

<tr>
<td>6</td>
<td>Acetylcholinesterase</td>
<td>AChE ↓</td>
<td>G</td>
<td>Cholinergic dysfunction ↓</td>
<td>Observed preclinically; no evidence supports equating MSM with clinically established AChE inhibitors.</td>
</tr>

<tr>
<td>7</td>
<td>Clinical Translation Constraint</td>
<td>No established human AD efficacy</td>
<td>G</td>
<td>Evidence limitation</td>
<td>Evidence consists primarily of animal neurotoxicity models despite demonstrated penetration of MSM into the human brain.</td>
</tr>
</table>
<p>P: 0–30 min&nbsp;&nbsp;&nbsp; R: 30 min–3 hr&nbsp;&nbsp;&nbsp; G: &gt;3 hr</p>

Pathway results for Effect on Cancer / Diseased Cells

Redox & Oxidative Stress(tgid=1) ⓘ

ROS↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 8,   BAX↑, 1,   Bcl-2↓, 1,   Bcl-xL↓, 1,   cl‑Casp3↑, 1,   Casp3↑, 2,   Casp7↑, 1,   cl‑Casp8↑, 1,   cl‑Casp9↑, 1,   Cyt‑c↑, 2,   necrosis↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Brk/PTK6↓, 1,   HER2/EBBR2↓, 1,   IGF-1R↓, 3,   JAK2↓, 1,   p‑JNK↑, 1,   STAT3↓, 3,   STAT5↓, 4,  

Transcription & Epigenetics(tgid=7) ⓘ

OCT4↓, 1,   SOX2↓, 1,   tumCV↓, 9,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP90↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   cl‑PARP↑, 2,   PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK4↓, 1,   cycD1/CCND1↓, 2,   P21↑, 1,   p27/CDKN1B↑, 1,   TumCCA↑, 5,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CSCs↓, 1,   IGF-1↓, 2,   IGF-1?, 1,   Nanog↓, 1,   TumCG↓, 2,   TumCP↓, 2,  

Migration(tgid=13) ⓘ

MMP2↓, 1,   MMP3↓, 1,   MMP9↓, 1,   TumCI↓, 2,   TumCMig↓, 3,   TumMeta↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

Hif1a↓, 1,   VEGF↓, 4,   VEGFR2/KDR/Flk1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

MMP↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 3,   Dose↝, 2,   eff↝, 2,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   HER2/EBBR2↓, 1,  

Functional Outcomes(tgid=23) ⓘ

TumVol↓, 2,  
Total Targets: 57

Pathway results for Effect on Normal Cells

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   Bil∅, 1,   Catalase↑, 2,   GPx↑, 2,   GPx4↓, 1,   GSH↑, 2,   HO-1↑, 1,   lipid-P↓, 1,   MDA↓, 1,   NOX↓, 1,   NRF2↑, 2,   ROS↓, 4,   ROS?, 1,   SOD↑, 2,   Trx1↑, 1,   uricA↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT∅, 1,  

Cell Death(tgid=5) ⓘ

iNOS↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

STAT↓, 1,  

Migration(tgid=13) ⓘ

Cartilage↑, 1,   TXNIP↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   IL1↓, 1,   IL1β↓, 2,   IL6↓, 2,   Inflam↓, 4,   Inflam↑, 1,   NF-kB↓, 2,   NLRP3↓, 3,   TNF-α↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,   BDNF↑, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,   p‑tau↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

ER(estro)↑, 1,   testos↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 3,   Dose?, 1,   eff↓, 1,   eff↑, 1,   Half-Life↝, 1,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT∅, 1,   AST∅, 1,   Bil∅, 1,   BP∅, 1,   creat∅, 1,   IL6↓, 2,   PC∅, 1,   WBC∅, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   AntiArt↑, 1,   chemoP↑, 1,   memory↑, 1,   Mood↑, 1,   neuroP↑, 1,   Pain↓, 3,   QoL↑, 1,   toxicity↓, 4,  
Total Targets: 60

Research papers

Year Title Authors PMID Link Flag
2026Methylsulfonylmethane (MSM) Mitigates Cisplatin-Induced Early Oxidative Testicular Dysfunction Through Modulation of Antioxidant Defense and GPX4 ResponsePelin İsmailoğluPMC13414715https://pmc.ncbi.nlm.nih.gov/articles/PMC13414715/0
2024Methylsulfonylmethane induces caspase-dependent apoptosis in acute myeloid leukemia cell linesYalda Hekmatshoar39114894https://pubmed.ncbi.nlm.nih.gov/39114894/0
2020Effect of Methylsulfonylmethane on Proliferation and Apoptosis of A549 Lung Cancer Cells Through G2/M Cell-cycle Arrest and Intrinsic Cell Death PathwayDoh Hoon Kim32234879https://pubmed.ncbi.nlm.nih.gov/32234879/0
2020Methylsulfonylmethane sensitizes endometrial cancer cells to doxorubicinKarolina KowalskaPMC8012311https://pmc.ncbi.nlm.nih.gov/articles/PMC8012311/0
2020Modulatory effect of methylsulfonylmethane against BPA/γ-radiation induced neurodegenerative alterations in rats: Influence of TREM-2/DAP-12/Syk pathwayMohamed K Abdel-Rafei32926927https://pubmed.ncbi.nlm.nih.gov/32926927/0
2020Beauty from within: Oral administration of a sulfur-containing supplement methylsulfonylmethane improves signs of skin ageingNeelam Muizzuddin32083522https://pubmed.ncbi.nlm.nih.gov/32083522/0
2020Methylsulfonylmethane Induces Cell Cycle Arrest and Apoptosis, and Suppresses the Stemness Potential of HT-29 CellsDoh Hoon Kim32878807https://pubmed.ncbi.nlm.nih.gov/32878807/0
2019Methylsulfonylmethane for treatment of low back pain: A safety analysis of a randomized, controlled trialPaul Crawford—https://www.sciencedirect.com/science/article/abs/pii/S09652299193064170
2018Methylsulfonylmethane (organic sulfur) induces apoptosis and decreases invasiveness of prostate cancer cellsKarolina Kowalska30339981https://pubmed.ncbi.nlm.nih.gov/30339981/0
2017DMSO modulates CNS function in a preclinical Alzheimer's disease modelLorène Penazzi—https://www.sciencedirect.com/science/article/pii/S00283908163047490
2017Methylsulfonylmethane: Applications and Safety of a Novel Dietary SupplementMatthew ButawanPMC5372953https://pmc.ncbi.nlm.nih.gov/articles/PMC5372953/0
2017Methylsulfonylmethane Induces G1 Arrest and Mitochondrial Apoptosis in YD-38 Gingival Cancer CellsNipin S P28373424https://pubmed.ncbi.nlm.nih.gov/28373424/0
2016Methylsulfonylmethane inhibits HER2 expression through STAT5b in breast cancer cellsDong Young Kang26648017https://pubmed.ncbi.nlm.nih.gov/26648017/0
2016The Influence of Methylsulfonylmethane on Inflammation-Associated Cytokine Release before and following Strenuous ExerciseMariè van der MerwePMC5097813https://pmc.ncbi.nlm.nih.gov/articles/PMC5097813/0
2016Methylsulfonylmethane Induces p53 Independent Apoptosis in HCT-116 Colon Cancer CellsArzu Zeynep KarabayPMC4964498https://pmc.ncbi.nlm.nih.gov/articles/PMC4964498/0
2015Methylsulfonylmethane inhibits NLRP3 inflammasome activationHuijeong Ahn25461402https://pubmed.ncbi.nlm.nih.gov/25461402/0
2015Methylsulfonylmethane and boswellic acids versus glucosamine sulfate in the treatment of knee arthritis: Randomized trialAngela NotarnicolaPMC5806735https://pmc.ncbi.nlm.nih.gov/articles/PMC5806735/0
2015The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in ER-positive breast cancer xenograftsNipin SPPMC4472404https://pmc.ncbi.nlm.nih.gov/articles/PMC4472404/0
2014Combination of AG490, a Jak2 inhibitor, and methylsulfonylmethane synergistically suppresses bladder tumor growth via the Jak2/STAT3 pathwayYoun Hee Joung24402583https://pubmed.ncbi.nlm.nih.gov/24402583/0
2014Methylsulfonylmethane suppresses hepatic tumor development through activation of apoptosisJoo-Hyun KimPMC3934636https://pmc.ncbi.nlm.nih.gov/articles/PMC3934636/0
2012Methylsulfonylmethane Suppresses Breast Cancer Growth by Down-Regulating STAT3 and STAT5b PathwaysEun Joung LimPMC3317666https://pmc.ncbi.nlm.nih.gov/articles/PMC3317666/0
2011Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled studyEytan M DebbiPMC3141601https://pmc.ncbi.nlm.nih.gov/articles/PMC3141601/0
2005Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trialL S Kim16309928https://pubmed.ncbi.nlm.nih.gov/163099280
2001Accumulation of methylsulfonylmethane in the human brain: identification by multinuclear magnetic resonance spectroscopyA Lin11641045https://pubmed.ncbi.nlm.nih.gov/11641045/0